LEADER 02479nam 2200601Ia 450 001 9910456485103321 005 20200520144314.0 010 $a1-281-76752-2 010 $a9786611767525 010 $a0-309-11867-0 035 $a(CKB)2550000000004405 035 $a(EBL)3378374 035 $a(SSID)ssj0000288925 035 $a(PQKBManifestationID)11220286 035 $a(PQKBTitleCode)TC0000288925 035 $a(PQKBWorkID)10383139 035 $a(PQKB)10130252 035 $a(MiAaPQ)EBC3378374 035 $a(Au-PeEL)EBL3378374 035 $a(CaPaEBR)ebr10237094 035 $a(CaONFJC)MIL176752 035 $a(OCoLC)923279005 035 $a(EXLCZ)992550000000004405 100 $a20080521d2008 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aAntivirals for pandemic influenza$b[electronic resource] $eguidance on developing a distribution and dispensing program /$fCommittee on Implementation of Antiviral Medication Strategies for an Influenza Pandemic, Board on Population Health and Public Health Practice, Institute of Medicine of the National Academies 210 $aWashington, DC $cNational Academies Press$dc2008 215 $a1 online resource (132 p.) 300 $aDescription based upon print version of record. 311 $a0-309-11866-2 320 $aIncludes bibliographical references. 327 $a""Front Matter""; ""Reviewers""; ""Contents""; ""Summary""; ""1 Introduction""; ""2 Antiviral Effectiveness, Safety, and Supply""; ""3 Ethics, Decision Making, and Communication""; ""4 Who Should Get Antivirals and Where?""; ""References""; ""Appendixes""; ""Appendix A: Summary of Lessons Learned from Other Mass Distribution Events""; ""Appendix B: State Plans""; ""Appendix C: Meeting One Agenda""; ""Appendix D: Meeting Two Agenda""; ""Appendix E: Committee Member Biographies"" 606 $aAntiviral agents$xEffectiveness 606 $aAntiviral agents 606 $aEpidemics$xPrevention 606 $aInfluenza$xPrevention 608 $aElectronic books. 615 0$aAntiviral agents$xEffectiveness. 615 0$aAntiviral agents. 615 0$aEpidemics$xPrevention. 615 0$aInfluenza$xPrevention. 676 $a614.518 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910456485103321 996 $aAntivirals for pandemic influenza$92198741 997 $aUNINA